[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100441118":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":31,"centralContacts":35,"locations":40,"responsibleParty":57,"collaborators":10,"id":61,"slug":10,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":64,"acronym":10,"eligibilityCriteria":65,"healthyVolunteers":62,"sex":66,"minAge":67,"maxAge":10,"enrollmentInfo":68,"targetDuration":10,"studyType":71,"phases":10,"briefSummary":72,"conditions":73,"keywords":81,"overallStatus":42,"whyStopped":10,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Massachusetts General Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"CAR T cells",null,"* Eligibility to participate on this study if enrolled on a DF\u002FHCC IRB corresponding main study and received infusion of CAR T cells\n* The research study procedures include evaluations and follow up visits: Timepoints of each evaluation and follow up visit- per protocol\n* Medical History\u002FPhysical Exam\n* Blood Test\n* Assessment of Disease: CT (Computerized Tomography) scan or PET-CT (Positron Emission Tomography-Computerized Tomography) scans.\n* Tumor biopsy.\n* Data Collection\n* Biobanking",[13,14,15],"Diagnostic Test: Disease assessments","Procedure: Tumor Biopsy","Diagnostic Test: Blood test",[17,22,27],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":10},"DIAGNOSTIC_TEST","Disease assessments","CT (Computerized Tomography) scan or PET-CT (Positron Emission Tomography-Computerized Tomography) scans as per protocol",[9],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":10},"PROCEDURE","Tumor Biopsy","Tumor Biopsy per protocol",[9],{"type":18,"name":28,"description":29,"armGroupLabels":30,"otherNames":10},"Blood test","Blood Test per protocol",[9],[32],{"name":33,"affiliation":5,"role":34},"Matthew J Frigault, MD","PRINCIPAL_INVESTIGATOR",[36],{"name":33,"role":37,"phone":38,"phoneExt":10,"email":39},"CONTACT","617-643-6175","mfrigault@mgb.org",[41],{"facility":5,"status":42,"city":43,"state":44,"zip":45,"country":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"RECRUITING","Boston","Massachusetts","02115","United States",{"type":48,"coordinates":49},"Point",[50,51],-71.05977,42.35843,{"lat":51,"lon":50},[54,56],{"name":33,"role":37,"phone":55,"phoneExt":10,"email":39},"(617) 724-4000",{"name":33,"role":34,"phone":10,"phoneExt":10,"email":10},{"type":58,"investigatorFullName":59,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Marcela V. Maus, M.D.,Ph.D.","Sponsor Investigator","100441118",false,"NCT05024175","Long-term Follow-up of Subjects Treated With CAR T Cells","Inclusion Criteria:\n\nSubjects will be asked to participate leading up to the last DF\u002FHCC corresponding main study visit.\n\nSubjects meeting the following criteria are eligible for study participation:\n\n* Provision of voluntary written informed consent by subject\n* CAR T cells were administered in DF\u002FHCC IRB corresponding main study\n\nExclusion Criteria:\n\nSubjects meeting the following criterion are to be excluded from study participation:\n\n\\- Subject unable to comply with study requirements","ALL","18 Years",{"count":69,"type":70},45,"ESTIMATED","OBSERVATIONAL","This is a single site, non-randomized, open-label, long-term safety and efficacy follow-up study for Phase 1 studies that evaluate the safety and efficacy of CAR T cells: NCT05660369 (DF\u002FHCC# 22-175) and NCT06026319 (DF\u002FHCC# 23-474).",[74,75,76,77,78,79,80],"Long Term Adverse Effects","CAR-T","Duty to Follow Up","Adult","Progression-Free Survival","Disease-Free Survival","Overall Survival",[82,83],"Long-Term Follow-up to CAR-T Cells","Follow-up Studies","2026-03-13",{"date":86,"type":87},"2026-03-16","ACTUAL",{"date":89,"type":87},"2023-08-07",{"date":91,"type":70},"2039-08-01",{"name":59,"class":6},1]